> ## Content Index
> Fetch the complete content index at: https://www.pennystocks.news/llms.txt
> Use this file to discover other available public pages before exploring further.

# A Cancer Drug Company Is Becoming Something Completely Different
- URL: https://www.pennystocks.news/howl-a-cancer-drug-company-is-becoming-something-completely/
- Published: 2026-08-21T17:15:04.000Z
- Updated: 2026-08-21T17:15:04.000Z
- Description: Existing shareholders will end up with about 6.8% of what the merged company becomes. The cancer pipeline they backed does not survive the deal.
- Author: PennyStocksNews Team
- Tags: nasdaq, ticker-howl

Werewolf Therapeutics built its pipeline around cancer. On Thursday it agreed to abandon that pipeline and merge with a company developing a treatment for a chronic pain condition that has no FDA-approved drug.

Werewolf Therapeutics, Inc. NASDAQ: HOWL 

For anyone holding Werewolf stock, the arithmetic is blunt: after the deal closes, **existing shareholders will own about 6.8% of the combined company**. Ambros shareholders take roughly 71.7%, and investors providing the new financing get about 21.5%.

The disease at the center of the new company is CRPS-1 — Complex Regional Pain Syndrome Type 1 — a condition that causes continuous, severe pain in a limb, typically following an injury. About 65,000 people in the United States are newly diagnosed each year, according to the companies' joint announcement, and **there is currently no FDA-approved medicine for it**.

Ambros's drug, neridronate, is already approved in Italy for CRPS and has been given to roughly 600,000 patients there across approved conditions. The FDA has granted it three priority designations — fast-track review, orphan drug status, and an intensive development-support program the agency reserves for drugs targeting serious conditions with high unmet need — and has indicated that a single successful Phase 3 trial could support a U.S. approval application, according to the release.

That trial, CRPS-RISE, is already running. Ambros expects **topline results in 2028**. The **$150 million raised in the concurrent financing** — co-led by RA Capital Management and Janus Henderson Investors — is expected to fund operations through those results and a planned application to the FDA, with **cash the companies say will last into the first half of 2029**.

Under the deal terms, **Ambros was valued at $500 million and Werewolf at $47.5 million**, based on the merger agreement's exchange ratio. Werewolf shareholders also receive the right to collect any payments the combined company receives if it sells Werewolf's existing cancer drug assets — what the announcement calls a contingent value right. No value for those assets is stated in the release.

The combined company will operate under the Ambros name and is expected to trade on Nasdaq under the ticker "AMBX." Every member of the incoming leadership team comes from Ambros. Werewolf's cancer programs do not follow.

Shares closed 111.41% higher at $0.9116, on dollar volume of about $226 million.

The deal requires shareholder approval from both companies and is **expected to close by the first quarter of 2027**. Whether Werewolf's legacy cancer assets ever produce a payment for former shareholders remains an open question; the release does not say whether any buyer has been approached.